THE EMERGING COMPANY OF THE YEAR 2011 & 2013:
Stempeutics has been awarded Bio Excellence Award as THE EMERGING COMPANY OF THE YEAR 2011& 2013 for outstanding contribution to BioPharma & Healthcare Sector by the Government of Karnataka, India.
Stempeucel® process patent bas been granted in 14 countries including USA, Japan, China, Singapore, Australia, New Zealand, UK, France, Germany, Italy and South Africa
ATMP & ODD Status in Europe:
Stempeucel® has been classified as an ATMP product by EMA and designated as an Orphan Drug for the treatment of CLI due to Buerger's Disease by EMA
Stempeutics has been awarded ISO 9001:2015 certification for "Development and Processing of Stem Cells for Clinical Trials and for Conducting Clinical Trials for chosen Indications: Critical Limb Ischemia(CLI) and Osteoarthritis (OA)" by TUV Rheinland in July 2018
Stempeutics Bangalore and Manipal R&D units have been recognised by Department of Scientific and Industrial Research (DSIR), Government of India
Stempeutics Manipal facility has been approved by DCGI for clinical trial manufacturing manufacturing (Form 29) as well as for commercial manufacturing (Form 28)
Dr Pawan Kumar is Asia Regional Secretary of International Society for Cellular Therapy.
BN Manohar is the Chairperson of ABLE (Association of Biotechnology Led Enterprise – India) – Regenerative Medicine sub-committee
India's hottest start-ups by Business Today in 2008
Dr Pawan Gupta is Industry representative of NAC-SCRT, Department of Health Research, Ministry of Health & Family Welfare. Government of India